Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program.
FINGER
cost effectiveness
costs
dementia
health economic simulation
prevention
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
16 Jul 2022
16 Jul 2022
Historique:
revised:
15
03
2022
received:
21
09
2021
accepted:
27
04
2022
entrez:
16
7
2022
pubmed:
17
7
2022
medline:
17
7
2022
Statut:
aheadofprint
Résumé
The aim of this study was to estimate the potential cost-effectiveness of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) program. A life-time Markov model with societal perspective, simulating a cohort of people at risk of dementia reflecting usual care and the FINGER program. Costs were 1,653,275 and 1,635,346 SEK and quality-adjusted life years (QALYs) were 8.636 and 8.679 for usual care and the FINGER program, respectively, resulting in savings of 16,928 SEK (2023 US$) and 0.043 QALY gains per person, supporting extended dominance for the FINGER program. A total of 1623 dementia cases were avoided with 0.17 fewer person-years living with dementia. The sensitivity analysis confirmed the conclusions in most scenarios. The model provides support that programs like FINGER have the potential to be cost-effective in preventing dementia. Results at the individual level are rather modest, but the societal benefits can be substantial because of the large potential target population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Research Council
ID : 804371
Pays : International
Organisme : Academy of Finland
ID : 317465
Organisme : Academy of Finland
ID : 287490
Organisme : Academy of Finland
ID : 294061
Organisme : Academy of Finland
ID : 319318
Organisme : EU Joint Programme - Neurodegenerative Disease Research (JPND)
ID : MIND-AD
Organisme : EU Joint Programme - Neurodegenerative Disease Research (JPND)
ID : EURO-FINGERS
Organisme : Alzheimerfonden
Organisme : Center for Innovative Medicine (CIMED) at Karolinska Institutet South Campus
Organisme : The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Organisme : RegionStockholm (ALF, NSV)
Organisme : Stiftelsen Stockholms sjukhem
Organisme : Swedish Research Councilfor Health Working Life and Welfare (FORTE)
Organisme : Finnish Social Insurance Institution
Organisme : Finnish Ministry of Education and Culture
Organisme : Juho Vainio Foundation, Finland
Organisme : Alzheimer's Research and PreventionFoundation, US
Organisme : The Swedish Associations of Local Authorities and Regions
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
WHO. Global Status Report on the Public Health Response to Dementia. In: WHO, editor. Geneva; WHO; 2021.
WHO. Dementia: A Public Health Priority. Geneva: WHO; 2012.
WHO. Seventieth World Health Assembly Update, 29 May 2017. In: WHO, editor. WHO; 2017.
WHO. Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. In: WHO, editor. Geneva: WHO; 2019.
WHO. Development of the Global Dementia Observatory. Geneva: WHO; 2021.
Winblad B, Amouyel P, Andrieu S, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455-532.
Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimers Res Ther. 2013;4:6.
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413-446.
Knapp M, Comas-Herrera A, Wittenberg R, et al. Scenarios of Dementia Care: What are the Impacts on Cost and Quality of Life? In: PSSRU, editor. London: Personal Social Services Research Unit, London School of Economics and Political Science; 2014.
Chibnik LB, Wolters FJ, Backman K, et al. Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. Eur J Epidemiol. 2017;32:931-938.
Wu YT, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol. 2017;13:327-339.
Mukadam N, Anderson R, Knapp M, et al. Effective interventions for potentially modifiable risk factors for late-onset dementia: a costs and cost-effectiveness modelling study. Lancet Healthy Longevity. 2020:e13-e20.
Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013;9:657-665.
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2256-2263.
Handels R, Wimo A. Challenges and recommendations for the health-economic evaluation of primary prevention programmes for dementia. Aging Ment Health. 2017:1-7.
Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735-741.
Zhang Y, Kivipelto M, Solomon A, Wimo A. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis. 2011;26:735-744.
Solomon A, Soininen H. Dementia: risk prediction models in dementia prevention. Nat Rev Neurol. 2015;11:375-377.
Whyte S, Dixon S, Faria R, et al. Estimating the cost-effectiveness of implementation: is sufficient evidence available? Value Health. 2016;19:138-144.
Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press; 1997.
Svensson M, Nilsson F. TLV:s betalningsvilja for nya lakemedel har analyserats - Kostnadseffektivitet och sjukdomens svarighetsgrad avgorande for subvention - cancerlakemedel far kosta mer. Lakartidningen. 2016;113:DX44.
TLV. Tillägg till uppdrag angående förberedande åtgärder med anledning av omregleringen av apoteksmarknaden (in Swedish). Stockholm 2009.
Basu A, Ganiats TG. Discounting in cost-effectiveness analysis. In: Neumann PJ, Ganiats TG, Russel LB, Sanders GD, Siegel JE, eds. Cost-Effectiveness in Health and Medicine. 2nd ed. Oxford Scholarship Online; 2016.
SverigesRiksbank. Annual average exchange rates. https://www.riksbank.se/en-gb/statistics/search-interest--exchange-rates/annual-average-exchange-rates/. Accessed March 19, 2018.
Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52:78-84.
Coley N, Hoevenaar-Blom MP, van Dalen JW, et al. Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials-rationale, preliminary evidence and challenges. Alzheimers Dement. 2020;16:1674-1685.
Anstey KJ, Zheng L, Peters R, et al. Dementia risk scores and their role in the implementation of risk reduction guidelines. Front Neurol. 2021;12:765454.
Solomon A, Handels R, Wimo A, et al. Effect of a multidomain lifestyle intervention on estimated dementia risk. J Alzheimers Dis. 2021;82:1461-1466.
Religa D, Fereshtehnejad SM, Cermakova P, et al. SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice. PLoS One. 2015;10:e0116538.
Handels R, Jönsson L, Garcia-Ptacek S, Eriksdotter M, Wimo A. Controlling for selective drop-out in longitudinal dementia data: application to the SveDem registry. Alzheimer Dement. 2020:16(5):789-796.
Wimo A, Handels R, Winblad B, et al. Quantifying and describing the natural history and costs of Alzheimer's disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75:891-902.
StatisticsSweden. Mortality rate per 1000 of the mean population by age and sex. Year 2000-2016. http://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE__BE0101__BE0101I/Dodstal/?rxid=f45f90b6-7345-4877-ba25-9b43e6c6e299. Accessed March 19, 2018.
Skoldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease - a simulation study. Curr Alzheimer Res. 2013;10:207-216.
Skoldunger A, Wimo A, Johnell K. Net costs of dementia in Sweden - an incidence based 10 year simulation study. Int J Geriatr Psychiatry. 2012;27:1112-1117.
Wimo A, Jonsson L, Fratiglioni L, et al. The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care. Alzheimers Res Ther. 2016;8:59.
Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621-635.
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jonsson L. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res. 2010;7:358-367.
Davis JC, Bryan S, Marra CA, Hsiung GY, Liu-Ambrose T. Challenges with cost-utility analyses of behavioural interventions among older adults at risk for dementia. Br J Sports Med. 2015;49:1343-1347.
Luepker RV, Rastam L, Hannan PJ, et al. Community education for cardiovascular disease prevention. Morbidity and mortality results from the Minnesota Heart Health Program. Am J Epidemiol. 1996;144:351-362.
Leong DP, Joseph PG, McKee M, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121:695-710.
WHO. Global health risks. Mortality and Burden of Disease Attributable to Selected Major Risks. In: WHO, editor. Geneva: WHO; 2009.
Jousilahti P, Laatikainen T, Peltonen M, et al. Primary prevention and risk factor reduction in coronary heart disease mortality among working aged men and women in eastern Finland over 40 years: population based observational study. BMJ. 2016;352:i721.
Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr. 2004;16:129-140.
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Curr Alzheimer Res. 2012;9:1050-1058.
Ngandu T, Lehtisalo J, Levalahti E, et al. Recruitment and baseline characteristics of participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)-a randomized controlled lifestyle trial. Int J Environ Res Public Health. 2014;11:9345-9360.
Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32-38.
Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14:653-666.
Marengoni A, Rizzuto D, Fratiglioni L, et al. The effect of a 2-year intervention consisting of diet, physical exercise, cognitive training, and monitoring of vascular risk on chronic morbidity-the FINGER randomized controlled trial. J Am Med Dir Assoc. 2018;19:355-360.
Lin PJ, Yang Z, Fillit HM, Cohen JT, Neumann PJ, Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. Health Aff (Millwood). 2014;33:547-554.
Kingston A, Robinson L, Booth H, Knapp M, Jagger C, project M. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age Ageing. 2018;47:374-380.